Search results for "Task force"

showing 10 items of 32 documents

Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics an…

2020

Precision cancer medicine (PCM) holds great promises to offer more effective therapies to patients based on molecular profiling of their individual tumours. Although the PCM approach seems intuitive, multiple conceptional and structural challenges interfere with the broad implementation of PCM into clinical practice. Accordingly, concerted national and international efforts are needed to guide the further development and broad adoption of PCM in Germany. With support of the 'German Cancer Aid' (Deutsche Krebshilfe [DKH]) a task force 'Molecular Diagnostics and Therapy' was implemented. In two workshops supported by the DKH, delegates from the fourteen comprehensive cancer centresidentified …

0301 basic medicineCancer ResearchCollaborative strategyConsensusDelphi TechniqueComputer scienceMedizinAntineoplastic AgentsComputer-assisted web interviewing03 medical and health sciences0302 clinical medicineCancer MedicinePredictive Value of TestsGermanyNeoplasmsHumansProfiling (information science)Molecular Targeted TherapyPrecision MedicineTask forceMolecular diagnosticsPrecision medicineEngineering management030104 developmental biologyMolecular Diagnostic TechniquesOncologyConceptual frameworkResearch Design030220 oncology & carcinogenesisEuropean Journal of Cancer
researchProduct

Identifying Biomarkers for Biological Age: Geroscience and the ICFSR Task Force

2021

The International Conference on Frailty and Sarcopenia Research Task Force met in March 2020, in the shadow of the COVID-19 pandemic, to discuss strategies for advancing the interdisciplinary field of geroscience. Geroscience explores biological mechanisms of aging as targets for intervention that may delay the physiological consequences of aging, maintain function, and prevent frailty and disability. Priorities for clinical practice and research include identifying and validating a range of biomarkers of the hallmarks of aging. Potential biomarkers discussed included markers of mitochondrial dysfunction, proteostasis, stem cell dysfunction, nutrient sensing, genomic instability, telomere d…

0301 basic medicineGerontologyAgingmedia_common.quotation_subjecthallmarks of agingTranslational researchfrailty03 medical and health sciencesSpecial Article030502 gerontologymedicineAnimalsHumansEpigeneticsFunction (engineering)Pandemicsresiliencemedia_commonGeroscienceSARS-CoV-2business.industryTask forceCOVID-19General Medicinemedicine.diseaseOmics030104 developmental biologyProteostasistranslational researchSarcopenia0305 other medical sciencebusinessBiomarkersThe Journal of Frailty & Aging
researchProduct

Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease.

2018

The diagnosis of Parkinson’s disease (PD) is based on clinical features and differently to the common opinion that detecting this condition is easy, seminal clinico-pathological studies have shown that up one-fourth of patients diagnosed as PD during life has an alternative diagnosis at post-mortem. The misdiagnosis is even higher when only the initial diagnosis is considered, since the diagnostic accuracy improves by time, during follow-up visits. Given that the confirmation of the diagnosis of PD can be only obtained through neuropathology, to improve and facilitate the diagnostic-therapeutic workup in PD, a number of criteria and guidelines have been introduced in the last three decades.…

0301 basic medicinemedicine.medical_specialtyParkinson's disease diagnostic criteriapreclinical Parkinson’s diseaseParkinson's diseaseParkinson’s disease guidelinesNeuropathologyDiseaseReviewlcsh:RC346-429prodromal Parkinson’s disease03 medical and health sciences0302 clinical medicinePreclinical Parkinson's diseasemedicineProdromal Parkinson's diseaseIntensive care medicinelcsh:Neurology. Diseases of the nervous systemJames Parkinsonbusiness.industryTask forceNoveltymedicine.diseaseClinical trial030104 developmental biologyNeurologyClinical diagnosisParkinson's disease guidelineParkinson’s disease diagnostic criteriaNeurology (clinical)Early phasebusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in neurology
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Left ventricular Myocardial dysfunction in arrhythmogenic cardiomyopathy with left ventricular involvement: A door to improving diagnosis.

2018

[EN] Background: Diagnostic Task Force Criteria (TFC) for arrhythmogenic cardiomyopathy (AC) exhibit poor performance for left dominant forms. TFC only include right ventricular (RV) dysfunction (akinesia, dyssynchrony, volumes and ejection fraction). Moreover, cardiac magnetic resonance imaging (CMRI) assessment of left ventricular (LV) dyssynchrony has hitherto not been described. Thus, we aimed to comprehensively characterize LVCMRI behavior in AC patients. Methods: Thirty-five AC patients with LV involvement and twenty-three non-affected family members (controls) were enrolled. Feature-tracking analysis was applied to cine CMRI to assess LV ejection fraction (LVEF), LV end-systolic and …

AdultMalemedicine.medical_specialtyHeart VentriclesCardiomyopathyMagnetic Resonance Imaging Cine030204 cardiovascular system & hematologyVentricular Function LeftStrainTECNOLOGIA ELECTRONICA03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineCardiac magnetic resonance imagingDiastoleInternal medicinemedicineLate gadolinium enhancementHumansCor030212 general & internal medicineLeft ventricular involvementVentricular dysfunctionCardiac magnetic resonance imagingArrhythmogenic Right Ventricular DysplasiaEjection fractionmedicine.diagnostic_testTask forcebusiness.industryLeft ventricular arrhythmogenic cardiomyopathyReproducibility of ResultsStroke VolumeMiddle Agedmedicine.diseasePatologiaDyssynchronyLv dyssynchronyCardiologyFemaleCardiology and Cardiovascular MedicineLEFT DOMINANTbusiness
researchProduct

A European survey of management approaches in chronic urticaria in children: EAACI Paediatric Urticaria Taskforce

2021

Background: Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0-18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for paediatric urticaria are implemented. Methods: The EAACI Taskforce for paediatric CU disseminated an online clinical survey among EAACI paediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centres. Results: The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly paediatric allergist…

Adultmedicine.medical_specialtyUrticariaImmunologyDermatologyOmalizumabOmalizumaburticaria diagnosischronic urticariaSecond lineSurveys and QuestionnairesHumansImmunology and AllergyMedicineChronic UrticariaChildChronic urticariachildurticaria treatmentbusiness.industryTask forceGuidelineThird lineFamily medicineChronic DiseasePediatrics Perinatology and Child HealthHistamine H1 AntagonistsomalizumabAllergistsApproaches of managementbusinessmedicine.drug
researchProduct

2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.

2021

Abstract Aim The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. Methods A WG was held between members of the international ESCEO task force and a group of Chinese experts. Results Non-pharmacological approach should be combined with pharmacological interventions. …

AgingChinaSymptomatic slow-acting drugs for osteoarthritisOsteoarthritis03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithm · ChinaConsensus Document030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryGeriatrics gerontologyTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis Kneemedicine.diseaseClinical PracticeAlgorithmPharmacological interventionsGeriatrics and GerontologybusinessAlgorithmAlgorithmsAging clinical and experimental research
researchProduct

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

2021

Abstract Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptoma…

AgingSymptomatic slow-acting drugs for osteoarthritisPharmacological managementOsteoarthritisSoutheast asianSoutheast asia03 medical and health sciences0302 clinical medicineMedicine and Health SciencesHumansMedicine030212 general & internal medicineLimited evidenceConsensus DocumentReimbursement030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis KneeKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithmmedicine.diseaseAlgorithmClinical PracticeGeriatrics and GerontologybusinessAlgorithmAlgorithms
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European…

2016

AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% female…

EUROASPIRE InvestigatorsMaleCardiac & Cardiovascular SystemsTime FactorsEpidemiologyCARDIOVASCULAR-DISEASE PREVENTIONCoronary DiseaseComorbidity030204 cardiovascular system & hematologyOverweightlaw.invention0302 clinical medicineRandomized controlled triallawRisk FactorsPrevalenceSecondary PreventionARTERY-DISEASE030212 general & internal medicineEUROASPIREguidelinesProspective StudiesPractice Patterns Physicians'Societies MedicalSecondary preventionGLUCOSE REGULATIONSmokingcardiovascular preventionRANDOMIZED CONTROLLED-TRIALMiddle AgedClinical PracticeEuropeTreatment OutcomePractice Guidelines as TopicCardiologyLDL Cholesterol LipoproteinsFemaleGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentCardiologyHEART-DISEASERisk Assessmentrehabilitation03 medical and health sciencesYoung AdultCardiovascular preventionSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansRisk factorCARDIAC REHABILITATIONExerciseAgedScience & TechnologyTask forcebusiness.industryCardiovascular AgentsDietCross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEHealth Care SurveysCardiovascular System & CardiologySmoking CessationSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCEEuropean journal of preventive cardiology
researchProduct